BACKGROUND: Resection of the T1 contrast-enhancing portion of glioblastoma multiforme (GBM) has been shown to increase patient survival, although whether GBM resection beyond these boundaries has an additional survival benefit is not clear. In this study, we examined the effect of resecting the enhancement and a margin of brain tissue surrounding the enhancement in patients with GBM of the temporal lobe. METHODS: We identified 32 consecutive patients with temporal lobe GBM who underwent initial resection between 2012 and 2015. Progression-free survival (PFS) and overall survival (OS) were analyzed based on the following categories: subtotal resection (STR; <99% of contrast enhancement removed), gross total resection (GTR; 100% of T1 contrast enhancement removed), and supramaximal resection (SMR; removal of T1 contrast enhancement plus removal of at least 1 cm of brain tissue surrounding the enhancement). RESULTS: Patients undergoing SMR demonstrated a substantially improved median PFS (15 months) compared with those undergoing GTR (7 months) or those undergoing STR (6 months) (P < 0.003). A median OS advantage was also present in the SMR group (24 months) compared with the GTR (11 months) and STR (9 months) groups (P < 0.004). SMR significantly improved PFS (hazard ratio [HR], 0.093; 95% confidence interval [CI], 0.01-0.89; P = 0.039) and OS (HR, 0.169; 95% CI, 0.05-0.57; P < 0.004) when controlling for other variables. The complication rates did not differ among the resection groups (P = 0.66). CONCLUSIONS: Achieving SMR substantially improved survival in patients with temporal lobe GBM compared with GTR of the enhancement alone.
BACKGROUND: Resection of the T1 contrast-enhancing portion of glioblastoma multiforme (GBM) has been shown to increase patient survival, although whether GBM resection beyond these boundaries has an additional survival benefit is not clear. In this study, we examined the effect of resecting the enhancement and a margin of brain tissue surrounding the enhancement in patients with GBM of the temporal lobe. METHODS: We identified 32 consecutive patients with temporal lobe GBM who underwent initial resection between 2012 and 2015. Progression-free survival (PFS) and overall survival (OS) were analyzed based on the following categories: subtotal resection (STR; <99% of contrast enhancement removed), gross total resection (GTR; 100% of T1 contrast enhancement removed), and supramaximal resection (SMR; removal of T1 contrast enhancement plus removal of at least 1 cm of brain tissue surrounding the enhancement). RESULTS:Patients undergoing SMR demonstrated a substantially improved median PFS (15 months) compared with those undergoing GTR (7 months) or those undergoing STR (6 months) (P < 0.003). A median OS advantage was also present in the SMR group (24 months) compared with the GTR (11 months) and STR (9 months) groups (P < 0.004). SMR significantly improved PFS (hazard ratio [HR], 0.093; 95% confidence interval [CI], 0.01-0.89; P = 0.039) and OS (HR, 0.169; 95% CI, 0.05-0.57; P < 0.004) when controlling for other variables. The complication rates did not differ among the resection groups (P = 0.66). CONCLUSIONS: Achieving SMR substantially improved survival in patients with temporal lobe GBM compared with GTR of the enhancement alone.
Authors: Christina Jackson; John Choi; Adham M Khalafallah; Carrie Price; Chetan Bettegowda; Michael Lim; Gary Gallia; Jon Weingart; Henry Brem; Debraj Mukherjee Journal: J Neurooncol Date: 2020-06-19 Impact factor: 4.130
Authors: Maureen Rakovec; Adham M Khalafallah; Oren Wei; David Day; Jason P Sheehan; Jonathan H Sherman; Debraj Mukherjee Journal: J Neurooncol Date: 2022-08-01 Impact factor: 4.506
Authors: Santiago Cepeda; Sergio García-García; Ignacio Arrese; Gabriel Fernández-Pérez; María Velasco-Casares; Manuel Fajardo-Puentes; Tomás Zamora; Rosario Sarabia Journal: Front Oncol Date: 2021-02-02 Impact factor: 6.244
Authors: Lasse Cramer Ahrens; Mathias Green Krabbenhøft; Rasmus Würgler Hansen; Nikola Mikic; Christian Bonde Pedersen; Frantz Rom Poulsen; Anders Rosendal Korshoej Journal: Cancers (Basel) Date: 2022-01-26 Impact factor: 6.639
Authors: Peter H Yang; Yu Tao; Jingqin Luo; Mounica Paturu; Hsiang-Chih Lu; Shakti Ramkissoon; Jonathan W Heusel; Eric C Leuthardt; Michael R Chicoine; Joshua L Dowling; Gavin P Dunn; Eric Duncavage; Sonika Dahiya; Arindam R Chattherjee; Albert H Kim Journal: Neurooncol Adv Date: 2022-01-10
Authors: Adham M Khalafallah; Maureen Rakovec; Chetan Bettegowda; Christopher M Jackson; Gary L Gallia; Jon D Weingart; Michael Lim; Yoshua Esquenazi; Brad E Zacharia; Ezequiel Goldschmidt; Mateo Ziu; Michael E Ivan; Andrew S Venteicher; Edjah K Nduom; Adam N Mamelak; Ray M Chu; John S Yu; Jason P Sheehan; Brian V Nahed; Bob S Carter; Mitchel S Berger; Raymond Sawaya; Debraj Mukherjee Journal: Neurosurgery Date: 2021-09-15 Impact factor: 5.315